Hepatic metabolism and biliary excretion of valerenic acid in isolated perfused rat livers: Role of Mrp2 (Abcc2)

Journal of Pharmaceutical Sciences

Volumn 98, Issue 10, 2009, Pages 3839-3849

  Maier Salamon, Alexandra ^a   Trauner, Gabriele ^a   Hiltscher, Romy ^a   Reznicek, Gottfried ^a   Kopp, Brigitte ^a   Thalhammer, Theresia ^b   Jäger, Walter ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Biliary excretion; Hepatic clearance; Hepatic metabolism; HPLC; Multidrug resistance associated protein 2; Valerenic acid

Indexed keywords

GLUCURONIDE; MULTIDRUG RESISTANCE PROTEIN 2; UNCLASSIFIED DRUG; VALERENIC ACID; VALERIAN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BILIARY EXCRETION; CONTROLLED STUDY; DRUG BILE LEVEL; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ISOLATION; DRUG METABOLISM; DRUG STRUCTURE; LIVER METABOLISM; LIVER PERFUSION; NONHUMAN; PROTEIN FUNCTION; RAT;

EID: 70349243158     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21671     Document Type: Article

References (40)

1. Houghton PJ. 1999. The scientific basis for the reputed activity of Valerian. J Pharm Pharmacol 51:505-512.
2. Bent S, Padula A, Moore D, Patterson M, Mehling W. 2006. Valerian for sleep: A systematic review and meta-analysis. Am J Med 119:1005-1012. (Pubitemid 44826933)
3. Valeriana radix. ESCOP Monographs. 2003. 2nd edition. Stuttgart: Thieme Verlag. pp 539-546.
4. Donath F, Quispe S, Diefenbach K, Maurer A, Fietze I, Roots I. 2000. Critical evaluation of the effect of valerian extract on sleep structure and sleep quality. Pharmacopsychiatry 33:47-53. (Pubitemid 30161106)
5. Hendriks H, Bos R, Woerdenbag HJ, Koster ASj. 1984. Central nervous depressant activity of Valerenic acid in the mouse. Planta Med 51:28-31. (Pubitemid 15146408)
6. Yuan C, Mehendale S, Xiao Y, Aung HH, Xie JT, Ang-Lee MK. 2004. The Gamma-aminobutyric acidergic effects of valerian and valerenic acid on rat brainstem neuronal activity. Anesth Analg 98:353-358. (Pubitemid 38129379)
7. Khom S, Baburin I, Timin E, Hohaus A, Trauner G, Kopp B, Hering S. 2007. Valerenic acid potentiates and inhibits GABA(A) receptors: Molecular mechanism and subunit specificity. Neuropharmacology 53:178-187. (Pubitemid 47125958)
8. A receptors by valerian extracts is related to the content of valerenic acid. Planta Med 74:19-24.
9. Dietz BM, Mahady GB, Pauli GF, Farnsworth NR. 2005. Valerian extract and valerenic acid are partial agonists of the 5-HT5a receptor in vitro. Brain Res Mol Brain Res 138:191-197.
10. Blumenthal M. 2003. The 2002 top-selling herbal supplements in food, drug and mass market retail outlets. HerbalGram 58:71.
11. Anderson GD, Elmer GW, Kantor ED, Templeton IE, Vitiello MV. 2005. Pharmacokinetics of valerenic acid after administration of valerian in healthy subjects. Phytotherapy Res 19:801-803. (Pubitemid 41571432)
12. Alkharfy KM, Frye RF. 2007. Effect of valerian, valerian/hops extracts, and valerenic acid on glucuronidation in vitro. Xenobiotica 37:113-123.
13. Hellum BH, Hu Z, Nilsen OG. 2007. The induction of CYP1A2, CYP2D6 and CYP3A4 by six trade herbal products in cultured primary human hepatocytes. Basic Clin Pharmacol Toxicol 100:23-30. (Pubitemid 46051439)
14. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Khan IA, Shah A. 2005. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther 77:415-426.
15. Valerian Root (monograph 0453). The European Pharmacopoeia. 2007. 6th edition. EDQM, European Directorate for the Quality of Medicines and Health Care (Ed.) Strasbourg, France.
16. Skonberg C, Olsen J, Madsen KG, Hansen SH, Grillo MP. 2008. Metabolic activation of carboxylic acids. Expert Opin Drug Metab Toxicol 4:425-438.
17. Wang M, Dickinson RG. 1998. Disposition and covalent binding of diflunisal and diflunisal acyl glucuronide in the isolated perfused rat liver. Drug Metab Dispos 26:98-104. (Pubitemid 28104075)
18. Lo A, Addison RS, Hooper WD, Dickinson RG. 2001. Disposition of naproxen, naproxen acyl glucuronide and its rearrangement isomers in the isolated perfused rat liver. Xenobiotica 31:309-319. (Pubitemid 32679310)
19. Jager W, Gehring E, Hagenauer B, Aust S, Senderowicz A, Thalhammer T. 2003. Biliary excretion of flavopiridol and its glucuronides in the isolated perfused rat liver: Role of multidrug resistance protein 2 (MRP2). Life Sci 73:2841-2854. (Pubitemid 37153358)
20. Maier-Salamon A, Hagenauer B, Reznicek G, Szekeres T, Thalhammer T, Jäger W. 2008. Metabolism and disposition of resveratrol in the isolated perfused rat liver: Role of MRP2 in the biliary excretion of glucuronides. J Pharm Sci 97:1615-1628. (Pubitemid 37153358)
21. Elferink RO, Groen AK. 2002. Genetic defects in hepatobiliary transport. Biochem Biophys Acta 1586:129-145.
22. Jansen P, Groothuis GMM, Peters WHM, Meijer DKF. 1987. Selective hepatobiliary transport defect for organic anions and neutral steroids in mutant rats with hereditary-conjugated hyperbilirubinemia. Hepatology 7:71-76. (Pubitemid 17019854)
23. Thalhammer T, Stapf V, Gajdzik L, Graf J. 1994. Bile canalicular cationic dye secretion as a model for P-glycoprotein mediated transport. Eur J Pharmacol 270:213-220. (Pubitemid 24112316)
24. Xiong H, Suzuki H, Sugiyama Y, Meier PJ, Pollack GM, Brouwer KL. 2002. Mechanisms of impaired biliary excretion of acetaminophen glucuronide after acute phenobarbital treatment or phenobarbital pretreatment. Drug Metab Dispos 30:962-969. (Pubitemid 34894647)
25. Liu JH, Smith PC. 2006. Predicting the pharmacokinetics of acyl glucuronides and their parent compounds in disease states. Curr Drug Metab 7:147-163.
26. Johnson CH, Wilson ID, Harding JR, Stachulski AV, Iddon L, Nicholson JK, Lindon JC. 2007. NMR spectroscopic studies on the in vitro acyl glucuronide migration kinetics of Ibuprofen ((+/-)-(R,S)-2-(4-isobutylphenyl) propanoic acid), its metabolites, and analogues. Anal Chem 15:8720-8727. (Pubitemid 350171385)
27. Kajbaf M, Barnaby RJ, Bottacini M, Bertolotti L, Ismail IM, Cholerton TJ, Pellegatti M. 2003. Pharmacokinetics, metabolism and excretion of the glycine antagonist GV150526A in rat and dog. Xenobiotica 33:415-428. (Pubitemid 36688117)
28. Corcoran O, Mortensen RW, Hansen SH, Troke J, Nicholson JK. 2001. HPLC/1H NMR spectroscopic studies of the reactive alpha-1-O-acyl isomer formed during acyl migration of S-naproxen beta-1-O-acyl glucuronide. Chem Res Toxicol 14:1363-1370. (Pubitemid 32983261)
29. Jedlitschky G, Hoffmann U, Kroemer HK. 2006. Structure and function of the MRP2 (ABCC2) protein and its role in drug disposition. Expert Opin Drug Metab Toxicol 2:351-366. (Pubitemid 46141403)
30. Mizuno N, Niwa T, Yotsumoto Y, Sugiyama Y. 2003. Impact of drug transporter studies on drug discovery and development. Pharmacol Rev 55:425-461. (Pubitemid 37013212)
31. -)-rats. Res Commun Mol Pathol Pharmacol 100:105-116.
32. Donner MG, Keppler D. 2001. Up-regulation of basolateral multidrug resistance protein 3 (Mrp3) in cholestatic rat liver. Hepatology 34:351-359. (Pubitemid 32702348)
33. Soroka CJ, Lee JM, Azzaroli F, Boyer JL. 2001. Cellular localization and up-regulation of multi-drug resistance-associated protein 3 in hepatocytes and cholangiocytes during obstructive cholestasis in rat liver. Hepatology 33:783-791. (Pubitemid 32246625)
34. Konig J, Rost D, Cui Y, Keppler D. 1999. Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane. Hepatology 29:1156-1163. (Pubitemid 29168750)
35. Chandra P, Brouwer KL. 2004. The complexities of hepatic drug transport: Current knowledge and emerging concepts. Pharm Res 21:719-735. (Pubitemid 39011292)
36. Romberg R, Olofsen E, Sarton E, den Hartigh J, Taschner PE, Dahan A. 2004. Pharmacokineticpharmacodynamic modeling of morphine-6-glucuronide induced analgesia in healthy volunteers: Absence of sex differences. Anesthesiology 100:120-133. (Pubitemid 38031663)
37. Scholz H, Schmitz W. 1984. Positive inotropic effects of digitoxin- and digoxin-glucuronide in human isolated ventricular heart muscle preparations. Basic Res Cardiol 79:134-139. (Pubitemid 14092518)
38. Vos RM, Krebbers SF, Verhoeven CH, Delbressine LP. 2002. The in vivo human metabolism of tibolone. Drug Metab Dispos 30:106-112.
39. Olson JA, Moon RC, Anders MW, Fenselau C, Shane B. 1992. Enhancement of biological activity by conjugation reactions. J Nutr 122:615-624.
40. Pasqualini JR, Chetrite GS. 2005. Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer. J Steroid Biochem Mol Biol 93:221-236.